Astrazeneca (AZN) Enterprise Value (2009 - 2026)

Astrazeneca (AZN) has reported Enterprise Value for 18 consecutive years, with -$7.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 47.55% year-over-year to -$7.9 billion; the TTM figure through Mar 2026 stood at -$7.9 billion (down 47.55% YoY), while the FY2025 annual figure was -$6.2 billion, down 427.59% from the prior year.
• Enterprise Value came in at -$7.9 billion for Q1 2026 at Astrazeneca, down from -$6.2 billion in the prior quarter.
• The five-year high for Enterprise Value was -$1.2 billion in Q4 2024, with the low at -$8.6 billion in Q3 2025.
• Average Enterprise Value over 5 years is -$5.9 billion, with a median of -$5.9 billion recorded in 2023.
• Across the five-year window, Enterprise Value surged 80.33% in 2024 and tumbled 427.59% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$6.2 billion in 2022, then grew by 4.8% to -$5.9 billion in 2023, then soared by 80.33% to -$1.2 billion in 2024, then sank by 427.59% to -$6.2 billion in 2025, then decreased by 28.16% to -$7.9 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$7.9 billion, -$6.2 billion, and -$8.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.